FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2515214902> ?p ?o ?g. }

• W2515214902 endingPage "742" @default.
• W2515214902 startingPage "733" @default.
• W2515214902 abstract "BackgroundThe pharmacokinetics and pharmacodynamics of antidiabetic therapies for patients with type 2 diabetes are often altered in the context of chronic kidney disease (CKD).Study DesignSystematic review and meta-analysis.Setting & PopulationPatients with type 2 diabetes and CKD.Selection Criteria for Studies2 reviewers independently screened studies identified through bibliographic databases (Cochrane Library, PubMed, Embase, International Pharmaceutical Abstracts), clinical trial registries, and references from pertinent articles and clinical practice guidelines. Eligible studies included randomized controlled trials evaluating incretin-based therapy in adults with type 2 diabetes and estimated glomerular filtration rates < 60 mL/min/1.73 m2.InterventionsIncretin-based therapies (dipeptidyl peptidase 4 inhibitors and glucagon-like peptide 1 receptor agonists) compared to placebo or active antidiabetic therapies.OutcomesChanges in glycated hemoglobin (HbA1c), hypoglycemia, mortality, change in fasting plasma glucose, cardiovascular events, and end-stage renal disease.ResultsOf 1,619 nonduplicate records screened, 13 studies were included. Compared to placebo, incretin-based therapies significantly reduced HbA1c levels (n = 9; weighted mean difference, −0.64; 95% CI, −0.79 to −0.48; I2 = 43%); however, compared with active comparators, they did not (n = 4; weighted mean difference, −0.07; 95% CI, −0.25 to 0.12; I2 = 38%). Incretin-based therapies significantly increased the risk for hypoglycemia compared to placebo (n = 7; relative risk [RR], 1.38; 95% CI, 1.01-1.89; I2 = 0%) but no effect was observed versus active comparators (n = 4; RR, 0.24; 95% CI, 0.03-1.94; I2 = 52%). Limited evidence exists for all-cause mortality (placebo: n = 7 [RR, 1.21; 95% CI, 0.64-2.29; I2 = 0%]; active comparators: n = 3 [RR, 0.70; 95% CI, 0.32-1.54; I2 = 0%]).LimitationsVariation among interventions, small number of studies, heterogeneity between studies, and high risk for attrition bias in 7 of the selected studies.ConclusionsIn patients with moderate or severe CKD, incretin-based therapies are effective in reducing HbA1c levels. Hypoglycemic events are rare, and wide CIs for the association preclude any definitive conclusions. Likewise, wide CIs were observed for mortality, cardiovascular events, and end-stage renal disease. The pharmacokinetics and pharmacodynamics of antidiabetic therapies for patients with type 2 diabetes are often altered in the context of chronic kidney disease (CKD). Systematic review and meta-analysis. Patients with type 2 diabetes and CKD. 2 reviewers independently screened studies identified through bibliographic databases (Cochrane Library, PubMed, Embase, International Pharmaceutical Abstracts), clinical trial registries, and references from pertinent articles and clinical practice guidelines. Eligible studies included randomized controlled trials evaluating incretin-based therapy in adults with type 2 diabetes and estimated glomerular filtration rates < 60 mL/min/1.73 m2. Incretin-based therapies (dipeptidyl peptidase 4 inhibitors and glucagon-like peptide 1 receptor agonists) compared to placebo or active antidiabetic therapies. Changes in glycated hemoglobin (HbA1c), hypoglycemia, mortality, change in fasting plasma glucose, cardiovascular events, and end-stage renal disease. Of 1,619 nonduplicate records screened, 13 studies were included. Compared to placebo, incretin-based therapies significantly reduced HbA1c levels (n = 9; weighted mean difference, −0.64; 95% CI, −0.79 to −0.48; I2 = 43%); however, compared with active comparators, they did not (n = 4; weighted mean difference, −0.07; 95% CI, −0.25 to 0.12; I2 = 38%). Incretin-based therapies significantly increased the risk for hypoglycemia compared to placebo (n = 7; relative risk [RR], 1.38; 95% CI, 1.01-1.89; I2 = 0%) but no effect was observed versus active comparators (n = 4; RR, 0.24; 95% CI, 0.03-1.94; I2 = 52%). Limited evidence exists for all-cause mortality (placebo: n = 7 [RR, 1.21; 95% CI, 0.64-2.29; I2 = 0%]; active comparators: n = 3 [RR, 0.70; 95% CI, 0.32-1.54; I2 = 0%]). Variation among interventions, small number of studies, heterogeneity between studies, and high risk for attrition bias in 7 of the selected studies. In patients with moderate or severe CKD, incretin-based therapies are effective in reducing HbA1c levels. Hypoglycemic events are rare, and wide CIs for the association preclude any definitive conclusions. Likewise, wide CIs were observed for mortality, cardiovascular events, and end-stage renal disease." @default.
• W2515214902 created "2016-09-16" @default.
• W2515214902 creator A5035233272 @default.
• W2515214902 creator A5042975334 @default.
• W2515214902 creator A5059327282 @default.
• W2515214902 creator A5074630811 @default.
• W2515214902 creator A5089010927 @default.
• W2515214902 date "2016-11-01" @default.
• W2515214902 modified "2023-09-27" @default.
• W2515214902 title "Safety and Efficacy of Incretin-Based Therapies in Patients With Type 2 Diabetes Mellitus and CKD: A Systematic Review and Meta-analysis" @default.
• W2515214902 cites W1596584892 @default.
• W2515214902 cites W1934604330 @default.
• W2515214902 cites W1964682623 @default.
• W2515214902 cites W1976425553 @default.
• W2515214902 cites W1987918436 @default.
• W2515214902 cites W1989566780 @default.
• W2515214902 cites W1997074317 @default.
• W2515214902 cites W2001097346 @default.
• W2515214902 cites W2007493806 @default.
• W2515214902 cites W2026963340 @default.
• W2515214902 cites W2033918355 @default.
• W2515214902 cites W2045321591 @default.
• W2515214902 cites W2059897529 @default.
• W2515214902 cites W2064130493 @default.
• W2515214902 cites W2071090755 @default.
• W2515214902 cites W2075182875 @default.
• W2515214902 cites W2079841945 @default.
• W2515214902 cites W2086357998 @default.
• W2515214902 cites W2096971003 @default.
• W2515214902 cites W2098292453 @default.
• W2515214902 cites W2100987099 @default.
• W2515214902 cites W2103075451 @default.
• W2515214902 cites W2104079863 @default.
• W2515214902 cites W2116077357 @default.
• W2515214902 cites W2118123147 @default.
• W2515214902 cites W2120251152 @default.
• W2515214902 cites W2120887783 @default.
• W2515214902 cites W2121162069 @default.
• W2515214902 cites W2125435699 @default.
• W2515214902 cites W2127854619 @default.
• W2515214902 cites W2129670822 @default.
• W2515214902 cites W2140536043 @default.
• W2515214902 cites W2151024604 @default.
• W2515214902 cites W2154277743 @default.
• W2515214902 cites W2160088494 @default.
• W2515214902 cites W2193379135 @default.
• W2515214902 cites W2236659707 @default.
• W2515214902 cites W2326175650 @default.
• W2515214902 cites W2904387867 @default.
• W2515214902 cites W4230159336 @default.
• W2515214902 doi "https://doi.org/10.1053/j.ajkd.2016.06.014" @default.
• W2515214902 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27528374" @default.
• W2515214902 hasPublicationYear "2016" @default.
• W2515214902 type Work @default.
• W2515214902 sameAs 2515214902 @default.
• W2515214902 citedByCount "30" @default.
• W2515214902 countsByYear W25152149022017 @default.
• W2515214902 countsByYear W25152149022018 @default.
• W2515214902 countsByYear W25152149022019 @default.
• W2515214902 countsByYear W25152149022020 @default.
• W2515214902 countsByYear W25152149022021 @default.
• W2515214902 countsByYear W25152149022022 @default.
• W2515214902 countsByYear W25152149022023 @default.
• W2515214902 crossrefType "journal-article" @default.
• W2515214902 hasAuthorship W2515214902A5035233272 @default.
• W2515214902 hasAuthorship W2515214902A5042975334 @default.
• W2515214902 hasAuthorship W2515214902A5059327282 @default.
• W2515214902 hasAuthorship W2515214902A5074630811 @default.
• W2515214902 hasAuthorship W2515214902A5089010927 @default.
• W2515214902 hasBestOaLocation W25152149021 @default.
• W2515214902 hasConcept C126322002 @default.
• W2515214902 hasConcept C134018914 @default.
• W2515214902 hasConcept C142724271 @default.
• W2515214902 hasConcept C151730666 @default.
• W2515214902 hasConcept C159641895 @default.
• W2515214902 hasConcept C204787440 @default.
• W2515214902 hasConcept C27081682 @default.
• W2515214902 hasConcept C2776442814 @default.
• W2515214902 hasConcept C2776453732 @default.
• W2515214902 hasConcept C2777180221 @default.
• W2515214902 hasConcept C2777538456 @default.
• W2515214902 hasConcept C2778653478 @default.
• W2515214902 hasConcept C2778881409 @default.
• W2515214902 hasConcept C2779284873 @default.
• W2515214902 hasConcept C2779343474 @default.
• W2515214902 hasConcept C2780012697 @default.
• W2515214902 hasConcept C2780031085 @default.
• W2515214902 hasConcept C2780533449 @default.
• W2515214902 hasConcept C2780668416 @default.
• W2515214902 hasConcept C44249647 @default.
• W2515214902 hasConcept C555293320 @default.
• W2515214902 hasConcept C71924100 @default.
• W2515214902 hasConcept C82789193 @default.
• W2515214902 hasConcept C86803240 @default.
• W2515214902 hasConcept C95190672 @default.
• W2515214902 hasConceptScore W2515214902C126322002 @default.
• W2515214902 hasConceptScore W2515214902C134018914 @default.
• W2515214902 hasConceptScore W2515214902C142724271 @default.

• next